1/19/2021 8:16:29 AM
TRACON Announces Acceptance Of The Envafolimab NDA By NMPA In China For Priority Review
12/30/2020 8:09:39 AM
TRACON Announces Acceptance Of Envafolimab NDA By The NMPA In China
12/29/2020 8:13:09 AM
TRACON Plans $5.0 Mln Registered Direct Offering
12/10/2020 8:25:52 AM
TRACON Reports Dosing Of First Patient In ENVASARC Registration Trial
10/26/2020 8:26:55 AM
TRACON Pharma: FDA Grants Orphan Drug Designation For TRC102 In Malignant Glioma, Incl Glioblastoma
8/17/2020 8:07:36 AM
TRACON Announces Clearance Of Pivotal ENVASARC Protocol After Filing Protocol With FDA
7/16/2020 8:20:27 AM
TRACON Pharma Announces Filing Of Pivotal ENVASARC Protocol With FDA
5/14/2020 8:46:39 AM
TRACON Plan To Present Positive Data From Envafolimab In Pivotal Trial In China
4/14/2020 8:22:39 AM
TRACON Appoints Shahe Garabedian As SVP Of Quality Assurance And Issuance Of An Inducement Award
3/19/2020 8:27:39 AM
TRACON Appoints Saundra Pelletier To Board
10/21/2019 8:10:04 AM
TRACON Enters Stock Purchase Agreement Of Up To $15 Mln With Aspire Capital
7/2/2019 8:10:48 AM
TRACON Pharma Issues Update On Phase 1/2 Trial Of TRC253 In Patients With Metastatic Castrate Resistant Prostate Cancer
4/12/2019 7:10:48 AM
TRACON Pharma Announces Termination Of Phase 3 TAPPAS Trial